In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Has Orthovita's Fight Finally Ended?

Executive Summary

Orthovita had spent the past eight years building up a small commercial pipeline while it ran its flagship bone augmentation material Cortoss through years of a demanding clinical trial. But two months after the FDA approved the product, the company had to clear another unforeseen hurdle: two controversial clinical trials.
Advertisement

Related Content

Vertebral Compression Fracture Treatments Under Pressure
Vertebral Compression Fracture Treatments Under Pressure
Baxter Spends Big on ApaTech to Join Orthobiologics Fray
Tighter FDA Review Squeezing Device VCs
Despite Surgeon Support, NEJM Vertebroplasty Articles Spark Slowdown, Reimbursement Review
Despite Surgeon Support, NEJM Vertebroplasty Articles Spark Slowdown, Reimbursement Review
Tighter FDA Review Squeezing Device VCs
Orthovita: The Most Natural Thing
Orthovita: The Most Natural Thing

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel